Wall Street analyst estimates for Prenetics Global Limited (PRE): consensus price target, buy/hold/sell recommendations and forecasts for revenue, EPS and EBITDA for the upcoming fiscal years.
Prenetics Global Limited is a consumer health sciences company that has pivoted to focus on a consumer health and longevity platform. The company's main brand is IM8, which offers science-backed nutritional supplements. It also operates CircleDNA, a consumer genetic testing brand that provides personalized health reports based on sequencing technology.
Recent Earnings Surprises
| Date | EPS Actual | EPS Est. | vs Est. |
|---|---|---|---|
| 2026-11-09 | $-0.80 | ||
| 2026-08-18 | $-0.53 | $-0.84 | +36.9% |
| 2026-06-10 | $-1.36 | $-0.49 | -177.6% |
| 2026-02-18 | $-1.75 | $-0.41 | -326.8% |
| 2025-11-10 | $-0.41 | $-0.55 | +25.5% |
| 2025-09-12 | $-0.82 | $-0.71 | -15.5% |
| 2025-06-12 | $-0.80 | $-0.80 | +0.0% |
| 2025-03-05 | $-0.94 | $-0.72 | -30.6% |
Valuation Ratios
| Price / Book | 4.43 |
| EV / EBITDA | -5.98 |
| Dividend Yield | 0.00% |
Income Statement (10y)
| Year | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|
| Revenue | $9.2M | $65.2M | $12.5M | $13.2M | $21.7M | $30.6M | $92.4M |
| Cost of Revenue | $6.5M | $38.8M | $8.9M | $9.5M | $12.9M | $15.2M | $43.6M |
| Gross Profit | $2.7M | $26.3M | $3.6M | $3.6M | $8.8M | $15.4M | $48.8M |
| Research & Development | $3.0M | $2.8M | $6.4M | $6.0M | $11.7M | $10.9M | $5.1M |
| Selling, General & Admin | $18.0M | $23.1M | $53.7M | $64.1M | $49.7M | $55.4M | $79.8M |
| Operating Expenses | $23.5M | $27.3M | $60.3M | $69.6M | $60.7M | $63.5M | $86.9M |
| Operating Income | -$20.8M | -$995126 | -$56.7M | -$66.0M | -$51.9M | -$48.1M | -$38.1M |
| EBITDA | -$18.6M | -$1.4M | -$209.2M | -$218.0M | -$47.9M | -$51.6M | -$32.2M |
| Interest Expense | $69390 | $59567 | $42229 | $242000 | $119662 | $203000 | $241000 |
| Pre-tax Income | -$20.9M | -$3.9M | -$216.6M | -$225.8M | -$56.7M | -$57.7M | -$36.2M |
| Income Tax | -$677474 | -$1.9M | $2.6M | -$245000 | -$269359 | -$7.9M | $34000 |
| Net Income | -$20.1M | -$1.9M | -$174.0M | -$190.5M | -$62.7M | -$46.3M | -$37.7M |
| EPS | $-2.73 | $-0.26 | $-47.04 | $-37.57 | $-5.58 | $-3.64 | $-2.68 |
| EPS (Diluted) | $-2.73 | $-0.26 | $-47.04 | $-37.57 | $-5.58 | $-3.64 | $-2.68 |
| Shares Outstanding (Diluted) | $7.4M | $7.4M | $3.7M | $5.1M | $11.2M | $12.7M | $14.1M |
Price
| Price | $24.19 |
| Market Cap | $411M |
| Exchange | NASDAQ |
| Country | HK |
Related companies: ARMP · ATLN · CDXS · IMDX · MXCT · OSUR · PROF
Explore sector: Healthcare · Medical - Diagnostics & Research
More sections of PRE: Overview · Financials · Valuation · Statistics · Technical · Ownership · News · Events
Discover more: Radar — undervalued stock signals · Investment Academy — learn to analyze stocks